# US Automated Cell Culture Equipment Market

> United States Automated Cell Culture Market Research Report: Size, Share, Trend Analysis - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.37%
- **2024:** $ 271.6 Million
- **2025:** $ 291.62 Million
- **2035:** $ 593.8 Million
- **Key Players:** Thermo Fisher Scientific (US), Merck KGaA (DE), Corning Incorporated (US), Becton, Dickinson and Company (US), Lonza Group AG (CH), GE Healthcare (GB), Sartorius AG (DE), Eppendorf AG (DE), F. Hoffmann-La Roche AG (CH)

**Report ID:** MRFR/HC/11826-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-automated-cell-culture-equipment-market-13351

---

## Market Summary

## US Automated Cell Culture Market Highlighted Trends & Dynamics

In 2019, the United States dominated the automated cell culture market, holding a substantial market share of 85.74%, valued at USD 404.8 million. The market is anticipated to maintain a robust growth trajectory with a projected Compound Annual Growth Rate (CAGR) of 13.08% during the forecast period. Meanwhile, Canada's market, valued at USD 67.3 million in 2019, is expected to witness a higher CAGR of 13.77%.

The modular automation segment played a pivotal role, capturing the majority of the market at 66.46% in 2019, with a market value of USD 313.8 million. This segment is poised for continued growth, expected to register a higher CAGR of 13.35% during the forecast period. In comparison, the whole lab automation segment, valued at USD 158.4 million in 2019, is projected to exhibit a CAGR of 12.83%.

Among equipment types, the automated liquid handling systems segment emerged as the market leader in 2019, commanding a share of 32.10% and a market value of USD 151.5 million. This segment is forecasted to sustain growth with an expected CAGR of 13.04%. The microplate readers segment, valued at USD 125.2 million in 2019, is projected to exhibit a CAGR of 13.34%. Notably, the automated storage & retrieval systems (ASRS) segment is anticipated to register the highest CAGR of 13.83%.

In terms of applications, the biopharmaceutical production segment claimed the largest market share at 22.04% in 2019, amounting to USD 104.1 million. This segment is projected to maintain a steady CAGR of 13.34% during the forecast period. The tissue engineering & regenerative medicine segment, valued at USD 81.9 million in 2019, is expected to exhibit a CAGR of 13.06%. On the other hand, the drug screening and development segment is anticipated to witness the highest CAGR of 13.83%.

In the end-user segment, pharmaceutical & biotechnology companies held the lion's share at 37.67% in 2019, with a market value of USD 177.8 million. This segment is poised for substantial growth, projected to register the highest CAGR of 13.93% during the forecast period. The research institutes segment, valued at USD 154.2 million in 2019, is expected to exhibit a CAGR of 12.84%.

Once again, within the modular automation segment, the market leader held a share of 66.31% in 2019, with a value of USD 268.5 million. This segment is expected to continue its dominance, registering a higher CAGR of 13.25% during the forecast period. Meanwhile, the whole lab automation segment, valued at USD 136.4 million in 2019, is projected to exhibit a CAGR of 12.73%.

Conclusively, the automated cell culture market's dynamic growth is evident across various segments, reflecting the industry's robust prospects and technological advancements.

## Market Drivers

### Rising Demand for Biopharmaceuticals

The increasing demand for biopharmaceuticals is a key driver for the automated cell-culture-equipment market. As the biopharmaceutical sector expands, the need for efficient and scalable cell culture processes becomes paramount. In the US, the biopharmaceutical market is projected to reach approximately $500 billion by 2025, necessitating advanced equipment to meet production demands. Automated cell-culture systems enhance productivity and reduce human error, making them essential for biopharmaceutical companies. This trend indicates a shift towards automation in laboratories, where precision and reproducibility are critical. The automated cell-culture-equipment market is likely to benefit from this growing sector, as companies seek to streamline their operations and improve output quality.

### Increased Focus on Personalized Medicine

The shift towards personalized medicine is reshaping the landscape of the automated cell-culture-equipment market. As healthcare moves towards tailored therapies, the need for precise and reproducible cell culture systems becomes increasingly important. Personalized medicine relies on the ability to culture patient-specific cells, which requires advanced automated systems to ensure consistency and reliability. The US market is witnessing a surge in research activities aimed at developing personalized therapies, which is likely to drive the demand for automated cell-culture equipment. This trend suggests that companies investing in automation will be better positioned to meet the evolving needs of the healthcare sector.

### Advancements in Cell Culture Technologies

Technological advancements in cell culture methodologies are significantly influencing the automated cell-culture-equipment market. Innovations such as 3D cell culture and organ-on-a-chip technologies are gaining traction, offering more physiologically relevant environments for cell growth. These advancements allow researchers to better mimic in vivo conditions, which is crucial for drug development and toxicity testing. The market for automated cell-culture equipment is expected to grow as laboratories adopt these cutting-edge technologies to enhance their research capabilities. Furthermore, the integration of artificial intelligence and machine learning in cell culture processes may lead to improved efficiency and data analysis, further driving the demand for automated solutions.

### Growing Investment in Research and Development

Investment in research and development (R&D) is a significant driver for the automated cell-culture-equipment market. As organizations, including academic institutions and private companies, allocate more resources to R&D, the demand for sophisticated cell culture technologies increases. In the US, R&D spending in the life sciences sector is projected to exceed $200 billion by 2025, highlighting the importance of advanced equipment in facilitating innovative research. Automated cell-culture systems provide researchers with the tools necessary to conduct experiments efficiently and effectively, thereby supporting the overall growth of the market. This trend indicates a robust future for automated solutions as R&D efforts continue to expand.

### Emphasis on Quality Control and Standardization

Quality control and standardization are becoming increasingly critical in the automated cell-culture-equipment market. As regulatory bodies impose stricter guidelines on laboratory practices, the need for reliable and consistent cell culture processes is paramount. Automated systems help ensure that cell cultures are maintained under controlled conditions, reducing variability and enhancing reproducibility. In the US, the emphasis on compliance with Good Manufacturing Practices (GMP) is driving laboratories to adopt automated solutions that facilitate adherence to these standards. This focus on quality is likely to propel the growth of the automated cell-culture-equipment market, as organizations seek to improve their operational efficiency and product quality.

## Future Outlook

The [Automated Cell Culture Equipment Market](https://www.marketresearchfuture.com/reports/automated-cell-culture-equipment-market-8770) is projected to grow at a 7.37% CAGR from 2025 to 2035, driven by technological advancements and increasing demand for biopharmaceuticals.

**New opportunities:**

- Integration of AI-driven analytics for real-time monitoring
- Development of customizable modular systems for diverse applications
- Expansion into emerging markets with tailored solutions

By 2035, the market is expected to achieve substantial growth and innovation.

## Segment Insights

### By lab automation type: Modular Automation (Largest) vs. Whole Lab Automation (Fastest-Growing)

In the US automated cell-culture-equipment market, modular automation holds the largest market share among lab automation types. This segment's strength lies in its adaptability and cost-effectiveness, allowing laboratories to implement automation incrementally while preserving existing workflows. It caters to a diverse range of applications, making it a preferred choice for many users seeking tailored solutions to optimize their processes.

Whole lab automation, the fastest-growing segment in this sector, is witnessing significant advancements driven by increased demand for efficiency and lab productivity. This trend is further fueled by a growing emphasis on high-throughput screening and data integration. As laboratories increasingly pursue comprehensive solutions to streamline operations, the adoption of whole lab automation is projected to accelerate, reflecting a shift towards fully integrated systems that offer seamless workflow management.

Automation Type: Modular Automation (Dominant) vs. Whole Lab Automation (Emerging)

Modular automation is characterized by its flexibility and ease of integration into existing lab environments, allowing users to customize their automation processes effectively. It typically consists of standalone modules that can be added or replaced as needs change, making it ideal for laboratories with varying workloads. This adaptability ensures that users get maximum value from their investments. In contrast, whole lab automation represents an emerging trend aimed at providing comprehensive solutions that encompass the entire laboratory workflow. These systems are designed for high-throughput environments and often incorporate advanced technologies such as AI and robotics, enabling laboratories to achieve remarkable efficiency gains and set a new standard in laboratory automation.

### By product type: Consumables (Largest) vs. Equipment (Fastest-Growing)

In the US automated cell-culture-equipment market, the product type segment is predominantly led by consumables, which have secured the largest market share due to their essential role in various cell culture processes. Equipment follows, contributing significantly to the market as well, with a focus on advanced tools that enhance laboratory efficiency and accuracy. Software, although smaller in terms of market share, remains a crucial component, supporting the integration and management of cell culture workflows.

The growth trends within this segment indicate a substantial increase in demand for equipment, driven by technological advancements and innovation in the field. As laboratories shift towards automation and more efficient workflows, the equipment segment is poised to expand rapidly. Consumables, while stable, will continue to support the fundamental aspects of cell culture, with ongoing developments enhancing their functionality and usability in diverse applications.

Consumables (Dominant) vs. Equipment (Emerging)

Consumables are the dominant force in the US automated cell-culture-equipment market, primarily due to their vital role in daily laboratory operations. Their widespread usage and necessity across research and industrial applications solidify their market position. In contrast, the equipment segment, marked as emerging, is witnessing rapid growth as new technologies are introduced. These innovations focus on automation and precision, enhancing productivity and efficiency in cell culture processes. As laboratories increasingly adopt sophisticated equipment, this segment is set to redefine operational standards. Despite being smaller in market share, the equipment segment's potential for growth is substantial as it meets the evolving needs of researchers and scientists.

### By application: Biopharmaceutical productions (Largest) vs. Vaccine production (Fastest-Growing)

In the US automated cell-culture-equipment market, biopharmaceutical productions hold the largest market share due to the increasing demand for biologics and monoclonal antibodies. This segment not only leads in revenue but also significantly influences R&D investments and technology advancements. Vaccine production, recognized as the fastest-growing segment, benefits from heightened global health awareness and rapid development cycles necessitated by recent pandemics.

The growth trends in these segments are driven by innovative research and the increasing prevalence of chronic diseases, prompting the need for advanced therapeutic solutions. Moreover, government initiatives and investments aimed at enhancing production capabilities in biopharmaceuticals, alongside the urgency for vaccine production post-COVID-19, are likely to sustain momentum in these applications over the coming years.

Biopharmaceutical productions (Dominant) vs. Vaccine production (Emerging)

Biopharmaceutical productions represent the dominant force within the US automated cell-culture-equipment market, characterized by extensive usage of sophisticated technologies to facilitate the production of complex biologics. This segment thrives due to a well-established regulatory framework and the pharmaceutical industry's focus on novel therapeutics. Conversely, vaccine production is emerging rapidly as a crucial area within the market. This segment is harnessing advanced cell-culture techniques to accelerate vaccine development and production processes. The convergence of these two sectors highlights a dynamic interplay where established practices in biopharmaceuticals are being adapted for emerging needs in vaccine technology, thereby enhancing overall effectiveness and efficiency in responding to global health challenges.

### By end-user: Pharmaceutical and Biotechnological Industries (Largest) vs. Hospitals and Diagnostic Labs (Fastest-Growing)

The US automated cell-culture-equipment market is primarily driven by the pharmaceutical and biotechnological industries, which dominate the market with the largest share due to their extensive investment in research and development. These segments utilize advanced cell-culture technologies to enhance drug discovery and production processes, leading to significant market presence and influence. In contrast, hospitals and diagnostic labs are witnessing rapid expansion, positioning themselves as the fastest-growing segment as they increasingly adopt cell-culture equipment for improved diagnostics and patient care.

Growth trends in this segment are largely influenced by technological advancements and increased funding within the pharmaceutical sector, fostering innovation and a higher demand for automated solutions. Additionally, growing regulatory requirements necessitate the adoption of high-precision equipment in hospitals and diagnostic labs, further contributing to their growth. This dynamic landscape suggests a shift in focus towards more efficient and reliable cell-culture methodologies, which will likely shape the future of this sector.

Pharmaceutical and Biotechnological Industries (Dominant) vs. Hospitals and Diagnostic Labs (Emerging)

In the US automated cell-culture-equipment market, the pharmaceutical and biotechnological industries serve as the dominant force, characterized by substantial investment and ongoing innovation. This segment is essential for drug development, utilizing sophisticated technologies that streamline cell culture processes, thus enabling significant advancements in therapeutic solutions. Conversely, hospitals and diagnostic labs represent an emerging segment, increasingly integrating automated cell-culture solutions to enhance diagnostic accuracy and reduce operational inefficiencies. As healthcare providers recognize the value of automation in improving patient outcomes and laboratory workflows, this segment is experiencing rapid growth. The shift is underscored by evolving healthcare practices that prioritize technology-driven solutions, establishing hospitals and diagnostic labs as vital players in the cell-culture equipment landscape.

## Competitive Benchmarking

The automated cell-culture-equipment market is characterized by a dynamic competitive landscape, driven by innovation, technological advancements, and increasing demand for biopharmaceuticals. Key players such as Thermo Fisher Scientific (US), Merck KGaA (DE), and Corning Incorporated (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Thermo Fisher Scientific (US) focuses on expanding its product portfolio through continuous innovation, while Merck KGaA (DE) emphasizes strategic partnerships to bolster its research capabilities. Corning Incorporated (US) is leveraging its expertise in materials science to develop advanced cell-culture solutions, thereby enhancing its competitive edge. Collectively, these strategies contribute to a robust competitive environment, fostering growth and innovation within the market.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several key players exerting considerable influence. This fragmentation allows for a diverse range of products and services, catering to various customer needs while fostering healthy competition among established and emerging players.
In October 2025, Thermo Fisher Scientific (US) announced the launch of a new automated cell-culture platform designed to streamline workflows and improve reproducibility in laboratory settings. This strategic move is likely to enhance the company's market share by addressing the growing demand for efficient and reliable cell-culture solutions. The introduction of this platform underscores Thermo Fisher's commitment to innovation and its ability to respond to evolving customer needs.
In September 2025, Merck KGaA (DE) entered into a collaboration with a leading biotechnology firm to develop next-generation cell-culture media. This partnership is expected to accelerate the development of innovative solutions that enhance cell growth and productivity. By aligning with a biotechnology leader, Merck KGaA is positioning itself to leverage cutting-edge research and expand its product offerings, thereby strengthening its competitive stance in the market.
In August 2025, Corning Incorporated (US) expanded its manufacturing capabilities by investing in a new facility dedicated to producing advanced cell-culture products. This investment not only signifies Corning's commitment to meeting increasing market demand but also enhances its operational capacity. The establishment of this facility is anticipated to improve supply chain reliability and reduce lead times, further solidifying Corning's position as a key player in the automated cell-culture-equipment market.
As of November 2025, current trends such as digitalization, sustainability, and AI integration are reshaping the competitive landscape. Companies are increasingly forming strategic alliances to enhance their technological capabilities and market reach. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is evident. Moving forward, competitive differentiation will likely hinge on the ability to innovate and adapt to emerging trends, ensuring that companies remain agile in a rapidly evolving market.

## Report Scope

| MARKET SIZE 2024 | 271.6(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 291.62(USD Million) |
| MARKET SIZE 2035 | 593.8(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.37% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Thermo Fisher Scientific (US), Merck KGaA (DE), Corning Incorporated (US), Becton, Dickinson and Company (US), Lonza Group AG (CH), GE Healthcare (GB), Sartorius AG (DE), Eppendorf AG (DE), F. Hoffmann-La Roche AG (CH) |
| Segments Covered | lab automation type, product type, application, end-user |
| Key Market Opportunities | Integration of artificial intelligence in automated cell-culture-equipment enhances efficiency and precision in research applications. |
| Key Market Dynamics | Technological advancements drive efficiency and precision in the automated cell-culture-equipment market, reshaping competitive dynamics. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current market valuation of the US automated cell-culture-equipment market?**
A: The market valuation was $271.6 Million in 2024.

**Q: What is the projected market valuation for the US automated cell-culture-equipment market by 2035?**
A: The projected valuation for 2035 is $593.8 Million.

**Q: What is the expected CAGR for the US automated cell-culture-equipment market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 7.37%.

**Q: Which companies are considered key players in the US automated cell-culture-equipment market?**
A: Key players include Thermo Fisher Scientific, Merck KGaA, Corning Incorporated, and Becton, Dickinson and Company.

**Q: What are the main segments of the US automated cell-culture-equipment market?**
A: The main segments include lab automation type, product type, application, and end-user.

**Q: What was the valuation of modular automation in the US automated cell-culture-equipment market in 2024?**
A: The valuation of modular automation was $108.5 Million in 2024.

**Q: How much is the whole lab automation segment projected to grow by 2035?**
A: The whole lab automation segment is projected to grow to $355.3 Million by 2035.

**Q: What is the expected growth in the consumables segment of the US automated cell-culture-equipment market?**
A: The consumables segment is expected to grow from $80.0 Million to $180.0 Million by 2035.

**Q: Which application segment is projected to have the highest valuation by 2035?**
A: Biopharmaceutical productions is projected to have the highest valuation, reaching $180.0 Million by 2035.

**Q: What is the anticipated growth in the pharmaceutical and biotechnological industries as end-users of automated cell-culture-equipment?**
A: This segment is expected to grow from $100.0 Million to $220.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-automated-cell-culture-equipment-market-13351*